Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: A systematic review of conclusions and assumptions

被引：56

作者：

Ogilvie, Isla ^{[1
]}

El Khoury, Antoine ^{[2
,3
]}

Cui, Yadong ^{[2
]}

Dasbach, Erik ^{[2
]}

Grabenstein, John D. ^{[2
]}

Goetghebeur, Mireille ^{[1
]}

机构：

[1] BioMedCom Consultants Inc, Montreal, PQ H9P 2V9, Canada

[2] Merck & Co Inc, West Point, PA 19486 USA

[3] Univ Arkansas Med Sci, Little Rock, AR 72205 USA

来源：

VACCINE | 2009年 / 27卷 / 36期

关键词：

Pneumococcal disease; Pneumococcal polysaccharide vaccine; Cost-effectiveness; Systematic review; STREPTOCOCCUS-PNEUMONIAE; CLINICAL EFFECTIVENESS; INFLUENZA VACCINATION; ECONOMIC EVALUATIONS; UNITED-STATES; DISEASE; EFFICACY; PEOPLE; POPULATION; BACTEREMIA;

D O I：

10.1016/j.vaccine.2009.05.061

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Streptococcus pneumoniae infections in adults are associated with substantial morbidity, mortality, and costs. A literature review was conducted to identify strengths and limitations of the cost-effectiveness of pneumococcal polysaccharide vaccine studies. A comparative analysis of the impact of model parameters on cost-effectiveness ratios was complemented by systematic assessment of the studies. We identified 11 economic evaluations of pneumococcal polysaccharide vaccine (PPV-23) in adults. In general, all 11 studies found that vaccination with PPV-23 is a cost-effective, and in some cases a cost-saving strategy for the prevention of invasive pneumococcal disease (IPD). The systematic assessment indicated that the results of the cost-effectiveness studies of PPV-23 are influenced by the values applied to vaccine efficacy, IPD incidence and case-fatality. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：4891 / 4904

页数：14

共 74 条

[1] Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults:: An international study [J].

Alanee, S. R. J. ;

McGee, L. ;

Jackson, D. ;

Chiou, C. C. ;

Feldman, C. ;

Morris, A. J. ;

Ortqvist, A. ;

Rello, J. ;

Luna, C. M. ;

Baddour, L. M. ;

Ip, M. ;

Yu, V. L. ;

Klugman, K. P. .

CLINICAL INFECTIOUS DISEASES, 2007, 45 (01) :46-51

[2] Cost-effectiveness of pneumococcal vaccination of older people:: A study in 5 western European countries [J].

Ament, A ;

Baltussen, R ;

Duru, G ;

Rigaud-Bully, C ;

de Graeve, D ;

Örtqvist, Å ;

Jönsson, B ;

Verhaegen, J ;

Gaillat, J ;

Christie, P ;

Cifre, AS ;

Vivas, D ;

Loiseau, C ;

Fedson, DS .

CLINICAL INFECTIOUS DISEASES, 2000, 31 (02) :444-450

[3]

ANDREWS BE, 1987, Q J MED, V62, P195

[4]

[Anonymous], 1997, MMWR Recomm Rep, V46, P1

[5]

[Anonymous], 2008, BMC Health Serv Res, DOI DOI 10.1186/1472-6963-8-270

[6]

*AUSTR GOV DEP HLT, GUID PHARM IND PREP

[7] Potential conflicts of interest in vaccine economics research: a commentary witha case study of pneumococcal conjugate vaccination [J].

Beutels, P .

VACCINE, 2004, 22 (25-26) :3312-3322

[8]

Beutels P, 2001, Expert Rev Pharmacoecon Outcomes Res, V1, P47, DOI 10.1586/14737167.1.1.47

[9] PNEUMOCOCCAL BACTEREMIA IN CHARLESTON COUNTY, SOUTH-CAROLINA - A DECADE LATER [J].

BREIMAN, RF ;

SPIKA, JS ;

NAVARRO, VJ ;

DARDEN, PM ;

DARBY, CP .

ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (07) :1401-1405

[10] Community-acquired pneumonia [J].

Brown, PD ;

Lerner, SA .

LANCET, 1998, 352 (9136) :1295-1302

← 1 2 3 4 5 6 7 8 →